vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
19.67
-0.03 (-0.15%)
Apr 21, 2025, 4:00 PM EDT - Market closed
vTv Therapeutics Revenue
In the year 2024, vTv Therapeutics had annual revenue of $1.02M. vTv Therapeutics had revenue of $17.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$1.02M
Revenue Growth
n/a
P/S Ratio
111.62
Revenue / Employee
$44,217
Employees
23
Market Cap
62.74M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VTVT News
- 4 weeks ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
- 5 weeks ago - vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - GlobeNewsWire
- 4 months ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire
- 5 months ago - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 9 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 10 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire